Emmanuelle Bettendorf, Account Manager, and Sandra Robert, Scientific Manager will participate next week to the 4th edition of the Neuroscience R&D technologies in Munich, 4th-5th October. Our Scientific Manager, Sandra Robelet, will launch a talk on the new preclinical strategy combining in vitro and in vivo models...
Inflammation and microglial activation is a common component of the pathogenesis for several neurodegenerative diseases, including Alzheimer's disease or Parkinson's disease. Microglia, the resident innate immune cells in the brain, actively monitor their environment but can become over-activated in response to diverse cues to produce...
Multiple studies have been performed to evaluate the effects of mesenchymal stem cells (MSCs) in preclinical Parkinson models. We performed a meta-analysis to estimate the treatment effect of unmodified MSCs on behavioral outcomes in preclinical studies of Parkinson's disease (PD). We performed a systematic literature search...
Alzheimer's disease (AD) is a progressive neuro-psychiatric disorder which is characterized by the formation of senile plaques (SPs), extracellular deposits of amyloid beta-peptides (Aβ) following intracellular neurofibrillary tangles (NFTs) of the microtubule-associated protein tau. Both cause neuronal degeneration, extensive loss of neurons and synaptic loss...
To characterize the expression in skin nerves of native (n-syn) and misfolded phosphorylated (p-syn) α-synucleins in pure autonomic failure (PAF) and idiopathic Parkinson disease (IPD). The specific aims were to (1) define the importance of n-syn and p-syn as disease biomarkers and (2) ascertain differences...
Researchers from the college of Pharmaceutical Sciences in China have recently studied a compound that enhances neuronal recovery in a rat model of Parkinson’s disease (Parkinson 6 OHDA). Parkinson’s disease is a chronic disorder of the central nervous system, caused primarily by the progressive loss...
Syncrosome, participated last week to the Neuroscience R&D Technologies Conference in London, to present key Parkinson's data. It was 2 very interesting days spent to discuss about the new advances in Imaging of Neurodegeneration, Alzheimer and Parkinson’s Disease and Drug Discovery, New trends in Preclinical animal...
L-DOPA remains the most effective therapy in the management of the motor symptoms of Parkinson's disease (PD). However, chronic treatment with levodopa is associated with the risk of development of motor fluctuations such as choreic and dystonic abnormal and involuntary movements affecting mainly the upper...
Vaccination is increasingly being investigated as a potential treatment for synucleinopathies, a group of neurodegenerative diseases including Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies associated with α-synuclein pathology. All lack a causal therapy. Development of novel, disease-altering treatment strategies is urgently needed....